The Latest Analyst Ratings for Denali Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have provided ratings for Denali Therapeutics (NASDAQ:DNLI), with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target is $31.5, with a high of $35.00 and a low of $28.00, representing a significant decrease from the previous target of $85.00. This suggests a potential downside of 62.94% from the earlier price target.
December 13, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Denali Therapeutics received 1 bullish and 3 somewhat bullish ratings from analysts, with a new average price target of $31.5, down from the previous $85.00, suggesting a potential downside.
The significant reduction in the average price target for DNLI by analysts suggests a bearish outlook on the stock's future performance. This could lead to a negative short-term impact on DNLI's stock price as the market adjusts to the new analyst expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100